LYB:NYSELyondellBasell Industries NV Analysis
Data as of 2026-03-13 - not real-time
$72.30
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
LyondellBasell is trading at $72.30, just below the computed resistance of $74.54 and well above the 20‑day SMA of $61.23, indicating strong upward momentum. The 20‑day SMA sits comfortably above the 50‑day ($55.00) and 200‑day ($52.75) averages, reinforcing a bullish trend, while the MACD line ($4.56) remains above its signal ($3.42) and the histogram is positive. However, the RSI of 74.6 signals an overbought condition that could precipitate a short‑term pullback. Volume is increasing, supporting the current rally, but the high 30‑day volatility of 55% and a beta of 1.24 suggest price swings may be pronounced.
On the fundamentals side, LYB delivers a 6.46% dividend yield with a modest 11.5% payout ratio, backed by $2.26 B of operating cash flow, yet the company carries a heavy debt load ($14.7 B) and a debt‑to‑equity ratio of 144%, reflecting significant leverage risk. Margins remain negative, but forward EPS of $4.18 points to an earnings recovery, and recent analyst upgrades from RBC, Fermium, Citigroup and KeyBanc provide a supportive outlook despite a consensus “hold.”
On the fundamentals side, LYB delivers a 6.46% dividend yield with a modest 11.5% payout ratio, backed by $2.26 B of operating cash flow, yet the company carries a heavy debt load ($14.7 B) and a debt‑to‑equity ratio of 144%, reflecting significant leverage risk. Margins remain negative, but forward EPS of $4.18 points to an earnings recovery, and recent analyst upgrades from RBC, Fermium, Citigroup and KeyBanc provide a supportive outlook despite a consensus “hold.”
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price is near resistance at $74.54
- RSI indicates overbought conditions
- High short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward EPS turnaround to $4.18
- Strong dividend yield with low payout ratio
- Analyst upgrades to Outperform/Buy
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Elevated debt‑to‑equity ratio
- Cyclic specialty chemicals sector
- Sustained high dividend yield
Key Metrics & Analysis
Financial Health
Revenue Growth-9.20%
Profit Margin-2.47%
P/E Ratio17.3
ROE-6.95%
ROA1.69%
Debt/Equity144.16
P/B Ratio2.3
Op. Cash Flow$2.3B
Free Cash Flow$447.0M
Technical Analysis
TrendBullish
RSI74.6
Support$54.27
Resistance$74.54
MA 20$61.23
MA 50$55.00
MA 200$52.75
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price$58.61
Upside/Downside-18.93%
GradeFair
TypeBlend
Dividend Yield6.46%
Risk Assessment
Beta1.24
Volatility55.16%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.